Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data with either EglN2 or control knockdown in T47D cells

ABSTRACT: In order to perform integrated analysis for EglN2 ChIP-Seq and microarray to identify EglN2 direct target genes, we performed the microarray analysis for T47D breast cancer cells with either control or EglN2 siRNA followed by hypoxia+DMOG treatment T47D cells were transfected with either control or EglN2 siRNA in duplicate with RNAi max. 36 hours following transfection, cells were treated with hypoxia (1%) and DMOG (1 mM) for 16 hours. Following treatment, total RNA was extracted using Rnaeasy kit from Qiagen.

ORGANISM(S): Homo sapiens

SUBMITTER: Zhang Qing

PROVIDER: S-ECPF-GEOD-59936 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Expression data with either EglN2 or control knockdown in T47D cells

2014-07-31 | GSE59936 | GEO

Expression data from WASF3 knockdown stable MDA-MB-231 cells and control cells

Project description:We recently showed that inactivation of the WASF3/WAVE3 gene in breast cancer cells results in loss of cell motility and invasion in vitro and metastasis in vivo. To obtain a better understanding of molecular mechanisms of action of WASF3, we have established the stable WASF3 knockdown MDA-MB-231 cells using shRNA strategy. We used microarrays to detail the global programme of gene expression after silencing WASF3 and identified distinct classes of up or down-regulated genes associated with breast cancer cell migration and motility The three stable WASF3 knockdown single clones and three control clones were selected for RNA extraction and hybridization on Affymetrix microarrays. To identify altered gene expression patterns in the knockdown cells, we compared gene expression levels between three different knockdown and three different control clones.

| S-ECPF-GEOD-26462 | biostudies-other

Expression data with either EglN2 or control knockdown in T47D cells

Project description:In order to perform integrated analysis for EglN2 ChIP-Seq and microarray to identify EglN2 direct target genes, we performed the microarray analysis for T47D breast cancer cells with either control or EglN2 siRNA followed by hypoxia+DMOG treatment T47D cells were transfected with either control or EglN2 siRNA in duplicate with RNAi max. 36 hours following transfection, cells were treated with hypoxia (1%) and DMOG (1 mM) for 16 hours. Following treatment, total RNA was extracted using Rnaeasy kit from Qiagen.

2014-07-31 | E-GEOD-59936 | biostudies-arrayexpress

Expression data for T47D cells treated with 2mM hydroxyurea

Project description:RAD51B, a paralog of RAD51, have been associated with breast cancer risk in genome-wide association studies. The underlying biological mechanism through which germline genetic variation in RAD51B confers susceptibility to breast cancer is not well understood. Here we investigate the molecular function of RAD51B in breast cancer cell lines. We used microarrays to detail the global gene expression to identify classes of genes that are regulated differnetly post DNA damages as a result of RAD51B depeletion. T47D cells were first transfected with either non-targeting (control; siCON) or RAD51B-targeting (experimental; siRAD51B) siRNA, then followed by 24hr treatment of 2mM hydroxyurea (HU). Total RNA were extracted at the end of the treatment for microarray analysis. Three biological replicates were carried out for both control and experimental samples.

| S-ECPF-GEOD-56940 | biostudies-other

Expression data for EglN2 conditional knockdown in T47D breast carcinoma cells

Project description:mRNA expression was assayed from T47D SCR and T47D EGLN2 conditional knock down cell lines in order to profile the gene expression pattern regulated by EGLN2.

2009-09-19 | GSE18171 | GEO

Expression data from knockdown of G9a in MDA-MB231 cells

Project description:G9a is an H3K9m2 methyltransferase, which is critical in controlling gene suppression and DNA methylation. We used microarray analysis to identify the target genes that are regulated by G9a in MDA-MB231 cells, in which E-cadherin is silenced. G9a expression was stably knocked-down in MDA-MB231 cells. RNA from this clone and parental (control) cells were purified for microarray analysis.

| S-ECPF-GEOD-34925 | biostudies-other

Expression data by ACLY knockdown

Project description:De novo lipogenesis is activated in most cancers. Several lipogenic enzymes are implicated in oncogenesis and represent potential cancer therapeutic targets. RNA interference-mediated depletion of ATP citrate lyase (ACLY), the enzyme that catalyzes the first step of de novo lipogenesis, leads to growth suppression in a subset of human cancer cells. Here we demonstrate the molecular basis and potential biomarkers for ACLY-targeting therapy. First, suppression of cancer cell growth by ACLY depletion involves down-regulation of fatty acid elongase ELOVL6 at the transcriptional level. Lipid profiling revealed that ACLY depletion alters fatty acid composition in triglyceride; increased palmitate and decreased longer fatty acids, in accordance with ELOVL6 down-regulation. Second, ACLY depletion increases reactive oxygen species (ROS), whereas addition of antioxidant reduces ROS and attenuates the growth suppression. Third, ACLY depletion or ROS stimulation induce phosphorylation of AMP-activated protein kinase (AMPK), a sensor of energy and lipid metabolism. Analysis of various cancer cell lines revealed that the levels of AMPK phosphorylation (p-AMPK) correlate with the basal ROS levels, and that cancer cells with low basal p-AMPK (i.e., low basal ROS) levels are highly susceptible to ACLY depletion-mediated growth suppression. Finally, in clinical colon cancer tissues, p-AMPK levels are significantly decreased in aggressive tumors and correlate with the levels of 8-hydroxydeoxyguanosine, a hallmark of ROS stimulation. Together, these data suggest that ACLY inhibition suppresses cancer growth via palmitate-mediated lipotoxicity, and p-AMPK could be a predictive biomarker for its therapeutic outcome. Two cell lines are treated with ACLY siRNA. The samples include controls of each cell line.

| S-ECPF-GEOD-37243 | biostudies-other

miRNA Expression data from WASF3 overexpressing stable T47D cells and control cells

2014-08-19 | GSE31367 | GEO

Expression data from CD44-knockdown MDA-MB-231 human breast cancer cells

Project description:CD44, an adhesion molecule that binds to extracellular matrix, primarily to hyaluronan (HA), has been implicated in cancer cell migration, invasion, and metastasis. CD44 has also recently been recognized as a marker for stem cells of several types of cancer. However, the roles of CD44 in the development of bone metastasis still remain unclear. To explore this issue, we established the MDA-MB-231 human breast cancer cells stably expressing short hairpin RNA against CD44. The CD44-knockdown MDA-MB-231 cells (MDA-MB-231 shCD44-2 and shCD44-3) were analyzed. As control, MDA-MB-231 cells stably expressing shRNA against firefly luciferase (shLuc) were used. Total of three samples. No replicates.

| S-ECPF-GEOD-45613 | biostudies-other

Expression data from T47D/S2 (control) and T47D/TR-2 (tamoxifen-resistant) cell lines

Project description:Basal expression profiling was performed to understand molecualr pathways specifically altered in tamoxifen-resistant cells. Tamoxifen is the most accepted targeted agent for treating patients with estrogen receptor (ER)-positive breast cancer (BC), but its efficacy has been limited due to drug resistance, manifested as disease recurrence and eventually death. Metabolic reprogramming of lipids has recently been recognized as a new mode of therapeutic resistance in various cancers. Therefore, we investigated previously unrecognized perturbations in lipid metabolism in tamoxifen-resistant BC by conducting comprehensive metabolomics and transcriptomics analysis.

2023-12-31 | GSE221439 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data